Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing
Autor: | Bo Zhang, Jianlin Xu, Shuhui Cao, Hua Zhong, Yue Wang, Jingwen Li |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Met amplification DNA sequencing 03 medical and health sciences 0302 clinical medicine Crizotinib Carcinoma Non-Small-Cell Lung Statistical significance Internal medicine Humans Medicine Lung cancer Survival analysis Retrospective Studies Massive parallel sequencing business.industry High-Throughput Nucleotide Sequencing medicine.disease 030104 developmental biology Gene Alteration 030220 oncology & carcinogenesis business medicine.drug |
Zdroj: | Lung Cancer. 149:17-22 |
ISSN: | 0169-5002 |
Popis: | Objectives Mesenchymal-epithelial transition (MET) amplification is a rare gene alteration in lung cancer. The aim of this study was to investigate the clinical characteristics of MET amplification in lung cancer and the response to crizotinib by subsets of patients with MET amplification detected by next-generation sequencing (NGS). Patients and methods We collected NGS sequencing data for patients with MET amplification in our institution from January 2018 to April 2019. The efficacy of crizotinib in MET amplification was retrospectively analyzed. Results A total of 2694 patients received NGS tests, 3.27 % (82/2507) of patients had primary MET amplification, and acquired MET amplification accounted for 16.04 % (30/187) of re-biopsy patients. Only 19 patients received monotherapy with crizotinib. In survival analysis, ten patients with copy number greater than 4 (CN > 4) had longer median PFS (mPFS) (4.76 months; 95 %CI: 1.67–7.85 months) compared with other nine patients (CN ≤ 4) (2.10 months; 95 %CI: 1.53–2.68 months; P = 0.063), but failed to get a statistical significance. No significant differences were observed between median PFS (mPFS) of the patients with primary and acquired MET amplification (4.04 months vs 2.76 months; P = 0.310). Conclusions Primary and acquired MET amplification were detected in 3.27 % and 16.04 % of lung cancer patients, respectively. Patients with CN > 4 seemed to have longer PFS after crizotinib treatment. No significant differences in PFS were observed between patients with primary and acquired MET amplification. |
Databáze: | OpenAIRE |
Externí odkaz: |